Unknown PHASE2 INTERVENTIONAL 2-arm NCT02116556

Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis (RIFA-AAH)

Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study

Sponsor: Germans Trias i Pujol Hospital

Updated 6 times since 2017 Last updated: Nov 3, 2016 Started: Apr 30, 2013 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02116556, this PHASE2 trial focuses on Alcoholic Hepatitis and remains ongoing. Sponsored by Germans Trias i Pujol Hospital, it has been updated 6 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Enrolling By Invitation → Unknown Status
Jun 2018 — Dec 2018 [monthly]

Enrolling By Invitation PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Enrolling By Invitation PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Germans Trias i Pujol Hospital
Hospital Universitari Vall d'Hebron Research Institute
Hospital de Sant Pau
Hospital del Mar

Data source: Hospital Universitari Vall d'Hebron Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain